Chronicling and predicting pharma's moves into digital
Focus on: The Future of Pharma
Chronicling and predicting pharma's moves into digital
It was only a few years ago that digital innovation at pharmaceutical companies was the province of tiny siloed innovation groups, churning out the odd companion app for a drug. These days, innovation is front and center, with big pharma acquiring, partnering and innovating in-house in all kinds of areas from digital therapeutics to remote clinical trials to connected drug delivery devices. And that's not even mentioning the incredible transformative power of AI for drug development or pharma's increasing presence as strategic investors in promising digital health companies.
The question is no longer, "Will pharma innovate?"; it's "How is pharma innovating?". In the month of July, we'll take a closer look at the many answers to this question, as well as exploring what the changing face of pharma means for other healthcare stakeholders.
CEO and President Dr. Corey McCann said that Somryst, a digital treatment for chronic insomnia and depression, is the first software as a medical device product to be submitted through the regulator's pilot pathway.
Researchers are working with digital therapeutics specialist Biofourmis, using machine learning technology and the Apple Watch to analyze dozens of physiology biomarkers.
For all the potential benefits of SaaS-based analytics and AI apps, privacy concerns remain, slowing data sharing and suggesting the need for new approaches to cloud security.
At BIO 2019, Sanofi's chief medical and digital officer advised fellow pharma leaders on embracing new technologies and preparing for the challenges they'll bring.
At BIO 2019 in Philadelphia, a panel of industry experts discussed their experiences with the FDA's pilot program; ambiguities in drug, device and software pathways; and the hurdles digital health regulation has yet to properly address.
The pair plans to use MC10's FDA-cleared wearable sensors, called BioStamp nPoint, to get insights into a patient's physiological data during the studies.